34 results on '"Yang, J.C-H."'
Search Results
2. OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial
3. P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION
4. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
5. OA04.04 The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study
6. P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%.
7. P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC.
8. MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA.
9. OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1.
10. OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
11. OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
12. EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
13. EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
14. EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
15. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
16. MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC
17. MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study
18. OA09.05 Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
19. OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
20. OA02.05 Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
21. 185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)
22. P1.12B.03 Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK+ NSCLC from the ALTA-1L Trial
23. 161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)
24. 29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
25. 30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
26. B09 The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
27. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
28. PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC
29. PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
30. OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01.
31. PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2).
32. 143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
33. OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors
34. LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.